Trials / Not Yet Recruiting
Not Yet RecruitingNCT07300059
Short-Term Glycemic Effects of Liquid Metformin vs Standard Tablets
Short-Term Glycemic Effects of Two Concentrations of Liquid Metformin Versus Standard Metformin Tablets in Healthy Adults
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Aspargo Labs, Inc · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, randomized study evaluating the short-term glycemic effects of two concentrations of liquid metformin formulations (100 mg/mL and 250 mg/mL) compared with standard immediate-release metformin tablets in healthy adult subjects. Participants will receive single or short-term doses of study treatments in a randomized sequence. Blood glucose measurements and other glycemic indicators will be collected to assess short-term pharmacodynamic effects. Safety and tolerability will also be monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liquid Metformin 100 mg/mL | A single oral dose of a liquid metformin formulation at a concentration of 100 mg/mL will be administered under fasting conditions in one period of the crossover to assess short-term glycemic effects and safety. |
| DRUG | Liquid Metformin 250 mg/mL | A single oral dose of a liquid metformin formulation at a concentration of 250 mg/mL will be administered under fasting conditions in one period of the crossover to assess short-term glycemic effects and safety. |
| DRUG | Standard Metformin Immediate-Release Tablet | A single oral dose of standard metformin immediate-release tablet(s) will be administered under fasting conditions in one period of the crossover to assess short-term glycemic effects and safety. |
Timeline
- Start date
- 2026-07-15
- Primary completion
- 2026-08-15
- Completion
- 2026-08-28
- First posted
- 2025-12-23
- Last updated
- 2025-12-23
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07300059. Inclusion in this directory is not an endorsement.